• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
s PowerPoint presentatio - ECDC
 

s PowerPoint presentatio - ECDC

on

  • 771 views

 

Statistics

Views

Total Views
771
Views on SlideShare
771
Embed Views
0

Actions

Likes
0
Downloads
12
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    s PowerPoint presentatio - ECDC s PowerPoint presentatio - ECDC Presentation Transcript

    • Spotlight Immunisation
      Three key messages on vaccine-preventable diseases
      ECDCEuropean Centre for Disease Prevention and Control
      Stockholm, 24 April 2010
    • Message 1
      Vaccines are powerful tools for protecting our health
    • Vaccines are powerful tools for protecting our health
      Immunisations have lead to the control and elimination of diseases in Europe that in the past caused death and disability for millions of people:
      • Prime examples for this are the global eradication of smallpox and the elimination of poliomyelitis from most regions of the world.
      • Diphtheria and tetanus are now under control in Europe and Haemophilusinfluenzae type b (Hib) infections in young children have been dramatically reduced.
      • The number of new hepatitis B infections has fallen significantly in Europe following the introduction of universal vaccination of children against the hepatitis B virus.
      • Pneumococcal conjugate vaccine (PCV), which is given to young infants, also indirectly protects unimmunised elderly people from pneumococcal pneumonia by reducing the risk of getting exposed to an infected child.
      • New vaccines licensed for use in the European Union include vaccines against human papilloma virus (HPV), herpes zoster virus, and rotavirus. A new 4-valent meningococcal vaccine improves protection against bacterial meningitis.
      • A new nasal preparation of a trivalent attenuated live influenza vaccine will soon simplify vaccination logistics, and an intradermal inactivated trivalent influenza vaccine could reduce vaccination costs.
    • Message 2
      Achieving and maintaining high vaccination coverage in Europe: the challenge remains
    • Vaccination: Challenges for public health
      A majority of Europeans appreciate the benefits of vaccines and trust the information and recommendations from immunisation programmes. A challenge for national programmes is to maintain and strengthen this trust in an environment where the risks and consequences of not being immunised are shifting out of focus.
      Public health strategies need to:
      • tackle "routine immunisation fatigue": some vaccine-preventable diseases have become so rare that parents, and sometimes even health professionals, fail to realise the benefits of immunisation;
      • develop and implement clear procedures for vaccine safety monitoring;
      • increase collaboration between national immunisation programmes and harmonise surveillance and reporting systems; and
      • strengthen surveillance for vaccine-preventable diseases.
    • Vaccination: Challenges for public health
      Causes of measles outbreaks include:
      • Pockets of unimmunised children among disadvantaged groups and vaccine sceptics are often the starting point for larger measles outbreaks.
      • Most measles outbreaks in Europe are imported from another European country.
      • Low overall vaccine coverage sustains outbreaks.
    • Measles incidence rates
      Figure 1a: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2001
      2001
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Measles incidence rates
      Figure 1b: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2002
      2002
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Measles incidence rates
      Figure 1c: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2003
      2003
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Measles incidence rates
      Figure 1d: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2004
      2004
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Measles incidence rates
      Figure 1e: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2005
      2005
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Measles incidence rates
      Figure 1f: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2006
      2006
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Measles incidence rates
      Figure 1g: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2007
      2007
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Measles incidence rates
      Figure 1h: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2008
      2008
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Measles incidence rates
      Figure 1i: Reported incidence of indigenous measles per 100 000 population, by EU/EEA country, 2009
      2009
      > 1
      0.1 – 1.0
      < 0.1
      0
      Not included or not reporting
      Source: ECDC
    • Message 3
      Measles elimination is within reach but needs more effort
    • Measles elimination
      • Because of ongoing measles outbreaks in Europe, the 2010 regional target1 will only be met by some countries, but the work towards measles elimination continues.
      • In 2008, more than 8 500 measles cases were reported in the EU/EEA countries, with more than 90% of the infected people lacking immunisation.
      • Recent measles outbreaks in Europe often began with an index case imported from another European country. In order to interrupt this transmission pattern, Europe needs a very high vaccination coverage, yet in some west European countries measles immunisation coverage has fallen below the 95% mark recommended by WHO.
      • Vaccination programmes against measles and rubella in Europe require political commitment and societal support. This includes special efforts to ensure easy access to vaccines, particularly for groups that already have difficulties accessing mainstream healthcare services.
      1World Health Organization (WHO) describes its target for measles elimination in Europe as an ‘interruption of indigenous measles transmission by 2010’. The definition of ‘interrupted transmission’ states that any imported outbreak will cease spontaneously and that the incidence of measles stays below 1 per 100 000 population.